Ads
related to: naepp asthma last update date- Register For A Webinar
Learn From Medical Professionals
Hear From Real Patients Like You
- Getting Started
Learn More About Dosing Schedules
Find Answers To Your Questions
- Register For A Webinar
Search results
Results From The WOW.Com Content Network
Bambuterol is a long-acting β adrenoceptor agonist (LABA) used in the treatment of asthma; ... This page was last edited on 26 August 2024, at 07:38 (UTC).
The FDA label was changed in April 2015, to add an indication for a once-daily treatment of asthma in people aged 18 years of age and older. [3] The exclusivity for a new product ended in May 2016, in the United States, and the exclusivity on the indication for asthma expired on 30 April 2018. [ 11 ]
[2] [3] [4] It is used in the management of asthma and chronic obstructive pulmonary disease (COPD). [4] It is used by inhaling the medication into the lungs. [4] Common side effects include thrush, headache, and cough. [5] Serious side effects may include worsening asthma, anaphylaxis, seizures, and heart problems. [5]
Overuse of β 2 agonists and asthma treatment without proper inhaled corticosteroid use has been associated with an increased risk of asthma exacerbations and asthma-related hospitalizations. [8] The excipients, in particular sulfite , could contribute to the adverse effects.
This article needs to be updated. ... Asthma. Chronic obstructive pulmonary disease ... This page was last edited on 11 January 2025, at 14:57 (UTC).
In 2000-2001 asthma prevalence was monitored at 6.5%; by 2010-2011 a 4.3% increase was shown, with asthma prevalence totaling 10.8% of Canada's population. [29] Furthermore, asthma prevalence varies among the provinces of Canada; the highest prevalence is Ontario at 12.1%, and the lowest is Nunavut at 3.8%. [29]
Aspirin-exacerbated respiratory disease (AERD), also called NSAID-exacerbated respiratory disease (N-ERD) or historically aspirin-induced asthma and Samter's Triad, is a long-term disease defined by three simultaneous symptoms: asthma, chronic rhinosinusitis with nasal polyps, and intolerance of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs).
EXHALE-4: [7] a global Phase III clinical trial to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma, is currently recruiting people ≥12 years old with a documented physician diagnosis of asthma who require treatment with at least low-dose inhaled corticosteroids and one other ...
Ad
related to: naepp asthma last update date